Grove Biopharma
Chicago, US · Founded 2020 · 30 employees on LinkedIn · 4 known investors
Find your way into Grove Biopharma
385 people in our graph share verified history with the Grove Biopharma team — schools, employers, funds. One of them is your warm intro.
Dan Lynchunlockedknows Geoffrey Duyk · together at Wesleyan University (overlapped)
×5knows the team · via Wesleyan University
×2knows the team · via Tpg
knows the team · via Howard Hughes Medical Institute (HHMI)
knows the team · via TPG
×2knows the team · via Case Western Reserve University School of Medicine
Grove Biopharma develops Bionic Biologics, a drug discovery platform combining AI-enabled molecular design, precision polymer chemistry, and experimental biology to target protein-protein interactions that are inaccessible to conventional therapeutics. The platform creates cell-penetrant, protein-scale molecules designed to engage intracellular targets for pharmaceutical applications.
Founders & leadership
GD
Geoffrey DuykinCEOGeoffrey Duyk holds an M.D. and Ph.D. from Case Western Reserve University and brings three decades of biotech industry experience spanning academic research (Assistant Professor at Harvard Medical School, Assistant Investigator at HHMI), drug discovery roles (VP of Genomics at Millennium Pharmaceuticals, President of R&D at Exelixis), and investment (Managing Director at TPG Biotechnology and co-founder of Circularis Partners). He is CEO of Grove Biopharma, which develops the Bionic Biologics platform for targeting intracellular protein-protein interactions in cancer and neurodegeneration.
GM
Geoffrey M. Duyk, M.D., Ph.D.inChief Executive OfficerGeoffrey Duyk holds an M.D. and Ph.D. from Case Western Reserve University and has spent three decades in biotechnology as an executive and investor, including roles as Vice President of Genomics at Millennium Pharmaceuticals, President of R&D at Exelixis, Managing Director at TPG Biotechnology, and co-founder of Circularis Partners; he is now Chief Executive Officer of Grove Biopharma, which develops a platform targeting intracellular protein-protein interactions for therapeutic applications.
Investors · 4
Funding
SEC filings, press & company announcements$30M disclosed across 1 of 2 rounds · 2025
- $30MSeries AApr 2025 · 3 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Grove Biopharma do?
- Grove Biopharma develops Bionic Biologics, a drug discovery platform combining AI-enabled molecular design, precision polymer chemistry, and experimental biology to target protein-protein interactions that are inaccessible to conventional therapeutics. The platform creates cell-penetrant, protein-scale molecules designed to engage intracellular targets for pharmaceutical applications.
- Who are Grove Biopharma's investors?
- Grove Biopharma's investors include DCVC (Data Collective), DCVC Bio, InVivium Capital, Portal Innovations.
- How much funding has Grove Biopharma raised?
- Grove Biopharma has disclosed $30M raised across 1 of its 2 known rounds.
- Where is Grove Biopharma headquartered?
- Grove Biopharma is headquartered in Chicago, US.